$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2016 Q4 Form 10-Q Financial Statement

#000114420416133341 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $170.0K $160.0K
YoY Change 1600.0%
% of Gross Profit
Research & Development $20.00K $45.17K
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K
YoY Change
% of Gross Profit
Operating Expenses $190.0K $212.5K
YoY Change 37900.0%
Operating Profit -$212.5K
YoY Change
Interest Expense $0.00 $1.971K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.971K
YoY Change
Pretax Income -$190.0K -$214.5K
YoY Change 1800.0% 2045.14%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$190.0K -$214.5K
YoY Change 37900.0% 2045.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.409K -$1.598K
COMMON SHARES
Basic Shares Outstanding 102.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $220.0K $30.00K
YoY Change
Cash & Equivalents $221.9K $33.46K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $221.9K $33.46K
YoY Change 347.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $100.6K $103.3K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $221.9K $33.46K
Total Long-Term Assets $100.6K $103.3K
Total Assets $322.5K $136.7K
YoY Change 550.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $66.39K $44.85K
YoY Change 348.49%
Accrued Expenses $4.879K $2.822K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $120.0K
YoY Change -25.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $453.9K $446.0K
YoY Change 453764.0% 147.75%
LONG-TERM LIABILITIES
Long-Term Debt $30.00K $30.00K
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $30.00K $30.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $453.9K $446.0K
Total Long-Term Liabilities $30.00K $30.00K
Total Liabilities $480.3K $471.9K
YoY Change 480203.0% 162.16%
SHAREHOLDERS EQUITY
Retained Earnings -$766.6K -$572.1K
YoY Change 153214.4%
Common Stock $608.8K $237.0K
YoY Change 1117.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$157.8K -$340.0K
YoY Change
Total Liabilities & Shareholders Equity $322.5K $136.7K
YoY Change 550.23%

Cashflow Statement

Concept 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$190.0K -$214.5K
YoY Change 37900.0% 2045.14%
Depreciation, Depletion And Amortization $0.00 $10.00K
YoY Change
Cash From Operating Activities -$190.0K -$120.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00 $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 380.0K 140.0K
YoY Change
NET CHANGE
Cash From Operating Activities -190.0K -120.0K
Cash From Investing Activities 0.000 -10.00K
Cash From Financing Activities 380.0K 140.0K
Net Change In Cash 190.0K 10.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$190.0K -$120.0K
Capital Expenditures $0.00 $10.00K
Free Cash Flow -$190.0K -$130.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
103281 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2016Q3 us-gaap Assets
Assets
136737 USD
CY2015Q4 us-gaap Assets
Assets
49600 USD
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
44849 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
0 USD
CY2016Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
100000 USD
CY2015Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0 USD
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2822 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 USD
CY2016Q3 us-gaap Management Fee Payable
ManagementFeePayable
280000 USD
CY2015Q4 us-gaap Management Fee Payable
ManagementFeePayable
0 USD
CY2016Q3 us-gaap Notes Payable Current
NotesPayableCurrent
15686 USD
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
101314 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
32010 USD
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
135637 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17990 USD
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-572106 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-500 USD
CY2016Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-335155 USD
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49500 USD
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136737 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49600 USD
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
445957 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
100 USD
CY2016Q3 us-gaap Liabilities
Liabilities
471892 USD
CY2015Q4 us-gaap Liabilities
Liabilities
100 USD
CY2016Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25000 USD
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0 USD
us-gaap Revenues
Revenues
0 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45174 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67566 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
164732 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
493484 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
212543 USD
CY2016Q3 us-gaap Interest Expense
InterestExpense
1971 USD
us-gaap Interest Expense
InterestExpense
3837 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-214514 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-571606 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-214514 USD
us-gaap Net Income Loss
NetIncomeLoss
-571606 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100621359 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90866349 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2637 USD
CY2016Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6719 USD
CY2016Q3 celz Working Capital Deficit
WorkingCapitalDeficit
412501 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001187953
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CELZ
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
102113750 shares
CY2016Q3 us-gaap Assets Current
AssetsCurrent
33456 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
49600 USD
CY2016Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2600 USD
CY2015Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
100 USD
CY2016Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
935 USD
CY2015Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0 USD
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101313750 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32010000 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101313750 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32010000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></b> <font style="FONT-SIZE: 10pt"> <i>-&#160;</i> The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. &#160;Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
34756 USD
us-gaap Share Based Compensation
ShareBasedCompensation
735 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20565 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3757 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
280000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-259830 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
125000 USD
celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
50000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4314 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
130000 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2500 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
303186 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
33356 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33456 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Stock Issued1
StockIssued1
100000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
24284 USD
us-gaap Notes Assumed1
NotesAssumed1
20000 USD
celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
8197 USD
celz Employee Service Sharebased Compensation Nonvested Awards Expiration Period
EmployeeServiceSharebasedCompensationNonvestedAwardsExpirationPeriod
2021

Files In Submission

Name View Source Status
0001144204-16-133341-index-headers.html Edgar Link pending
0001144204-16-133341-index.html Edgar Link pending
0001144204-16-133341.txt Edgar Link pending
0001144204-16-133341-xbrl.zip Edgar Link pending
celz-20160930.xml Edgar Link completed
celz-20160930.xsd Edgar Link pending
celz-20160930_cal.xml Edgar Link unprocessable
celz-20160930_def.xml Edgar Link unprocessable
celz-20160930_lab.xml Edgar Link unprocessable
celz-20160930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg14img1_ex10-2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v452531_10q.htm Edgar Link pending
v452531_ex10-1.htm Edgar Link pending
v452531_ex10-2.htm Edgar Link pending
v452531_ex10-3.htm Edgar Link pending
v452531_ex31-1.htm Edgar Link pending
v452531_ex31-2.htm Edgar Link pending
v452531_ex32-1.htm Edgar Link pending
v452531_ex32-2.htm Edgar Link pending